Adaptive Biotechnologies Corporation $ADPT Shares Sold by Braidwell LP

Braidwell LP decreased its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 80.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 736,014 shares of the company’s stock after selling 3,127,093 shares during the period. Braidwell LP owned 0.48% of Adaptive Biotechnologies worth $11,011,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter valued at $30,000. Smartleaf Asset Management LLC raised its stake in shares of Adaptive Biotechnologies by 593.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after buying an additional 3,371 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth $133,000. Keybank National Association OH acquired a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $155,000. Finally, Caprock Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $163,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Harlan S. Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,193,403.22. Following the transaction, the insider directly owned 1,522,058 shares of the company’s stock, valued at $20,045,503.86. This trade represents a 23.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sharon Benzeno sold 63,103 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $831,066.51. Following the completion of the sale, the insider owned 272,751 shares of the company’s stock, valued at approximately $3,592,130.67. This trade represents a 18.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 2,464,588 shares of company stock valued at $36,222,545. Company insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Stock Up 5.8%

Shares of NASDAQ ADPT opened at $13.17 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. The business has a fifty day simple moving average of $16.55 and a 200-day simple moving average of $15.87.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.Adaptive Biotechnologies’s revenue was up 51.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.23) EPS. As a group, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ADPT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.